Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
Biologics Boost | Waters Corporation strategically positions itself in the rapidly expanding biologics market, with acquisitions and product developments strengthening its offerings in this high-growth sector. |
Financial Health | Explore Waters' robust financial metrics, including a 59.3% gross profit margin and nearly $3 billion in annual revenue, underpinning its strategic initiatives and market expansion. |
Market Dynamics | Delve into the projected 10.3% CAGR of the biologics market through 2028, and how Waters' specialized expertise in QA/QC for biopharmaceuticals positions it for potential outperformance. |
Analyst Outlook | Analyst price targets range from $360 to $460, reflecting varied perspectives on Waters' growth potential amid its focus on high-growth areas like GLP-1 treatments and biologics. |
Metrics to compare | WAT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWATPeersSector | |
---|---|---|---|---|
P/E Ratio | 27.2x | 6.6x | −0.5x | |
PEG Ratio | 2.52 | 0.01 | 0.00 | |
Price/Book | 8.3x | 1.1x | 2.6x | |
Price / LTM Sales | 5.9x | 1.5x | 3.2x | |
Upside (Analyst Target) | 12.7% | 31.9% | 38.8% | |
Fair Value Upside | Unlock | 23.8% | 5.4% | Unlock |